Advertisement

Related Videos

Opening Session Panel Discussion

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Welcome and Introduction to Vi3C

Advertisement

Advertisement




Dec
08
Today In Oncology
MRD Proven to Be a Strong Individual-Level Predictor of Survival in AML
Black Patients With AML Face Younger Onset and Significantly Worse Survival Outcomes
Fixed-Duration Doublet Noninferior to Continuous Ibrutinib in CLL
Study Identifies Rectal Bleeding as Key Predictor of Early-Onset Colorectal Cancer
Nivolumab and Ipilimumab in Advanced dMMR/MSI-H Noncolorectal Cancers
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo